Johnson & Johnson, Pharmacyclics, Inc.'s Closely Watched Leukemia Drug Effective In Long Term Study

Published: Dec 09, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

A closely watched leukemia drug developed by Johnson & Johnson and Pharmacyclics Inc maintained its effectiveness in keeping the disease at bay for most patients, according to long-term follow-up data from a midstage study being presented at a major medical meeting. The oral drug, ibrutinib, last month won U.S. approval to treat a rare and aggressive form of non-Hodgkin lymphoma known as mantle cell lymphoma. It is awaiting a Food and Drug Administration decision on treating chronic lymphocytic leukemia (CLL), a slowly progressing form of blood cancer that primarily affects people aged 65 and older.

Help employers find you! Check out all the jobs and post your resume.

Back to news